Next generation therapeutics for Alzheimer's disease
Abstract: To date, no truly effective therapy has been developed for Alzheimer's disease or mild cognitive impairment. In searching for new approaches that may succeed where previous ones have failed, it may be instructive to consider the successful therapeutic developments for other chronic illnesses such as cancer and human immunodeficiency virus.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Next generation therapeutics for Alzheimer's disease ; volume:5 ; number:6 ; year:2013 ; pages:795-798 ; extent:4
EMBO molecular medicine / European Molecular Biology Organization ; 5, Heft 6 (2013), 795-798 (gesamt 4)
- Creator
-
Bredesen, Dale E.
John, Varghese
- DOI
-
10.1002/emmm.201202307
- URN
-
urn:nbn:de:101:1-2023020306591507255913
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bredesen, Dale E.
- John, Varghese
Other Objects (12)
Next-generation Alzheimer’s Therapeutics: Leveraging Deep Biology
Recent developments in Alzheimer's disease therapeutics
Modified nucleic acids: replication, evolution, and next-generation therapeutics
Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing
Synthetic Gene Circuits for Regulation of Next‐Generation Cell‐Based Therapeutics
Next Generation Rice Disease Research
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics
Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics
Chemical entity normalization for successful translational development of Alzheimer’s disease and dementia therapeutics
Next-generation Alzheimer’s Therapeutics: Leveraging Deep Biology
Recent developments in Alzheimer's disease therapeutics
Modified nucleic acids: replication, evolution, and next-generation therapeutics
Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing
Synthetic Gene Circuits for Regulation of Next‐Generation Cell‐Based Therapeutics
Next Generation Rice Disease Research
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics
Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics
Chemical entity normalization for successful translational development of Alzheimer’s disease and dementia therapeutics
Next-generation Alzheimer’s Therapeutics: Leveraging Deep Biology
Recent developments in Alzheimer's disease therapeutics
Modified nucleic acids: replication, evolution, and next-generation therapeutics
Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing
Synthetic Gene Circuits for Regulation of Next‐Generation Cell‐Based Therapeutics
Next Generation Rice Disease Research
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics
Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics